If standard once-weekly semaglutide dosing isn't optimizing your results, genetic data can guide switching to tirzepatide, microdose protocols, or dual-compound options like GLP-Squared
Commonly prescribed GLP-1 receptor agonists in the UK include: Semaglutide (Ozempic, Wegovy, Rybelsus [oral formulation]) Dulaglutide (Trulicity) Liraglutide (Victoza, Saxenda) Exenatide (Byetta [twice-daily], Bydureon [weekly]) Tirzepatide (Mounjaro) - a dual GIP/GLP-1 receptor agonist with similar considerations [6] [7] These medications are typically administered via subcutaneous injection (daily, twice-daily or weekly depending on the specific formulation), with semaglutide also available as an oral tablet
The findings indicate that semaglutide may influence the activity of BMSCs and could be an appropriate medication for people with type 2 diabetes and osteoporosis
It is available in both once-weekly injections and daily oral formats
This 60-90 minute appointment includes discussion of your goals, previous weight loss attempts, and any barriers you've encountered
GLP-1 and Patulous Eustachian Tube: When Weight Loss Becomes an ENT Complaint June 2026 June 2026 As GLP-1 receptor agonists continue to gain widespread use for obesity and diabetes management, ENT specialists may begin observing an increase in patients presenting with symptoms consistent with Patulous Eustachian Tube (PET) dysfunction following significant or rapid weight loss
